TY - JOUR
T1 - Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution
AU - Ferman, Tanis J.
AU - Aoki, Naoya
AU - Boeve, Bradley F.
AU - Aakre, Jeremiah A.
AU - Kantarci, Kejal
AU - Graff-Radford, Jonathan
AU - Parisi, Joseph E.
AU - Van Gerpen, Jay A.
AU - Graff-Radford, Neill R.
AU - Uitti, Ryan J.
AU - Pedraza, Otto
AU - Murray, Melissa E.
AU - Wszolek, Zbigniew K.
AU - Reichard, R. Ross
AU - Fields, Julie A.
AU - Ross, Owen A.
AU - Knopman, David S.
AU - Petersen, Ronald C.
AU - Dickson, Dennis W.
N1 - Funding Information:
This study was funded by NIH P50-AG16574, U01-NS100620, the Mangurian Foundation for Lewy body disease research, the Little Family Foundation, the Uehara Memorial Foundation, the Turner Foundation, and the Robert H. and Clarice Smith and Abigail van Buren Alzheimer Disease Research Program.
Funding Information:
T.J. Ferman is supported by the Mangurian Foundation for Lewy body disease research and NIH. N. Aoki reports no disclosures relevant to the manuscript. B.F. Boeve has received research funding from Axovant and Biogen; receives royalties from the publication of Behavioral Neurology of Dementia (Cambridge Medicine, 2009, 2017); serves on the Scientific Advisory Board of the Tau Consortium; and is supported by the Little Family foundation, the Turner Foundation, the Mangurian Foundation, and NIH. J.A. Aakre reports no disclosures relevant to the manuscript. K. Kantarci serves on the data safety monitoring board for Takeda Global Research and Development Center, Inc.; data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy; and receives research support from Avid Radiopharmaceuticals and Eli Lilly, the Alzheimer’s Drug Discovery Foundation, and NIH. J. Graff-Radford receives research funding from NIH. J.E. Parisi and J.A. Van Gerpen report no disclosures relevant to the manuscript. N. Graff-Radford receives research support from Lilly, Biogen, Novartis, AbbVie, and NIH. R.J. Uitti has received research funding from Boston Scientific and receives compensation from the American Academy of Neurology for serviceinaneditorialcapacityforNeurology®. O. Pedraza is supported by the Mangurian Foundation for Lewy body disease research. M.E. Murray receives research funding from NIH. Z.K. Wszolek receives research support from AbbVie, Biogen, and NIH. R.R. Reichard and J.A. Fields report no disclosures relevant to the manuscript. O.A. Ross receives research funding from NIH. D.S. Knopman serves on a data safety monitoring board for the DIAN study and receives research support from Lilly Pharmaceuticals, Biogen, the Alzheimer’s Treatment and Research Institute at USC, and NIH. R.C. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare; receives royalties from publishing Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from NIH. D.W. Dickson is an editorial board member for Acta Neuropathologica, Brain, Brain Pathology, Neuropathology and Applied Neurobiology, Annals of Neurology, and Neuropathology, and editor for the International Journal of Clinical and Experimental Pathology and American Journal of Neurodegenerative Disease; and is supported by the Mangurian Foundation for Lewy body disease research and NIH. Go to Neurology.org/N for full disclosures.
Publisher Copyright:
© American Academy of Neurology.
PY - 2020/7/14
Y1 - 2020/7/14
N2 - Objective To determine whether Lewy body disease subgroups have different clinical profiles.MethodsParticipants had dementia, autopsy-confirmed transitional or diffuse Lewy body disease (TLBD or DLBD) (n = 244), or Alzheimer disease (AD) (n = 210), and were seen at least twice (mean follow-up 6.2 ± 3.8 years). TLBD and DLBD groups were partitioned based on the presence or absence of neocortical neurofibrillary tangles using Braak staging. Four Lewy body disease subgroups and AD were compared on clinical features, dementia trajectory, and onset latency of probable dementia with Lewy bodies (DLB) or a DLB syndrome defined as probable DLB or dementia with one core feature of parkinsonism or probable REM sleep behavior disorder.ResultsIn TLBD and DLBD without neocortical tangles, diagnostic sensitivity was strong for probable DLB (87% TLBD, 96% DLBD) and the DLB syndrome (97% TLBD, 98% DLBD) with median latencies <1 year from cognitive onset, and worse baseline attention-visual processing but better memory-naming scores than AD. In DLBD with neocortical tangles, diagnostic sensitivity was 70% for probable DLB and 77% for the DLB syndrome with respective median latencies of 3.7 years and 2.7 years from cognitive onset, each associated with tangle distribution. This group had worse baseline attention-visual processing than AD, but comparable memory-naming impairment. TLBD with neocortical tangles had 48% diagnostic sensitivity for probable DLB and 52% for the DLB syndrome, with median latencies >6 years from cognitive onset, and were cognitively similar to AD. Dementia trajectory was slowest for TLBD without neocortical tangles, and fastest for DLBD with neocortical tangles.ConclusionsThe phenotypic expression of DLB was associated with the distribution of α-synuclein and tau pathology.
AB - Objective To determine whether Lewy body disease subgroups have different clinical profiles.MethodsParticipants had dementia, autopsy-confirmed transitional or diffuse Lewy body disease (TLBD or DLBD) (n = 244), or Alzheimer disease (AD) (n = 210), and were seen at least twice (mean follow-up 6.2 ± 3.8 years). TLBD and DLBD groups were partitioned based on the presence or absence of neocortical neurofibrillary tangles using Braak staging. Four Lewy body disease subgroups and AD were compared on clinical features, dementia trajectory, and onset latency of probable dementia with Lewy bodies (DLB) or a DLB syndrome defined as probable DLB or dementia with one core feature of parkinsonism or probable REM sleep behavior disorder.ResultsIn TLBD and DLBD without neocortical tangles, diagnostic sensitivity was strong for probable DLB (87% TLBD, 96% DLBD) and the DLB syndrome (97% TLBD, 98% DLBD) with median latencies <1 year from cognitive onset, and worse baseline attention-visual processing but better memory-naming scores than AD. In DLBD with neocortical tangles, diagnostic sensitivity was 70% for probable DLB and 77% for the DLB syndrome with respective median latencies of 3.7 years and 2.7 years from cognitive onset, each associated with tangle distribution. This group had worse baseline attention-visual processing than AD, but comparable memory-naming impairment. TLBD with neocortical tangles had 48% diagnostic sensitivity for probable DLB and 52% for the DLB syndrome, with median latencies >6 years from cognitive onset, and were cognitively similar to AD. Dementia trajectory was slowest for TLBD without neocortical tangles, and fastest for DLBD with neocortical tangles.ConclusionsThe phenotypic expression of DLB was associated with the distribution of α-synuclein and tau pathology.
UR - http://www.scopus.com/inward/record.url?scp=85088179324&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088179324&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000009763
DO - 10.1212/WNL.0000000000009763
M3 - Article
C2 - 32561678
AN - SCOPUS:85088179324
SN - 0028-3878
VL - 95
SP - E155-E165
JO - Neurology
JF - Neurology
IS - 2
ER -